177 E COLORADO BLVD, PASADENA, CA
Reports Fiscal 2026 Third Quarter Results
Appointment of Dr. Matt Cohen as Director at Arrowhead Pharmaceuticals
Reports Fiscal 2026 Second Quarter Results
Arrowhead Pharmaceuticals Elects Seven Directors at Annual Meeting
Reports Fiscal 2026 First Quarter Results
Annual Report to Security Holders
Arrowhead Pharmaceuticals Issues $700 Million Convertible Senior Notes
Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Q3
Q2
Q1
FY 2024
Amended Annual Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Free Writing Prospectus
Prospectus filed pursuant to Rule 305(b)(2)